The global Dyspareunia Treatment Market was valued at USD 689.0 million in 2021 and is projected to reach USD 1.02 billion by the end of 2031, growing at a CAGR of 4.1% from 2022 to 2031. This steady growth is driven by increasing demand across key end-use industries, gradual technological advancements, and expanding applications in emerging markets, supported by rising investments and evolving consumer preferences.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85106

Market Overview

Genital pain during or after sexual activity is known as dyspareunia or coitalgia. Painful sex can be experienced internally in the vagina, uterus, or pelvis as well as outwardly on the vulva. Sexual activity can be uncomfortable due to infections or underlying medical issues. Usually, the underlying source of discomfort is found and treated. Rise in number of women with painful coitus is expected to propel the global market during the forecast period. Dyspareunia treatment market trends include rise in prevalence of dyspareunia, which is augmenting the research and development in painful intercourse treatment or painful coitus treatment. Leading players in the market are investing and collaborating on novel drug options for dyspareunia treatment or coitalgia treatment.

Analysts’ Viewpoint

A new non-estrogen topical medication called prasterone (Intrarosa) is available in the market and is licensed for the treatment of moderate-to-severe dyspareunia caused due to menopause. There have not been any direct comparison studies between prasterone and vaginal estrogen. In one trial, prasterone outperformed placebo and increased the female sexual function index scores after just 12 weeks of treatment. Prasterone is thought to function by locally converting androstenedione and testosterone to estrone and estradiol in the vagina. Most doctors consider this to be the second-line treatment for patients who do not wish to use estrogen due to its daily dosage and lack of proven superiority to estrogen. Additionally, less insurance coverage could be available for newer brand-name drugs such as Intrarosa and Imvexxy than for more seasoned estrogen supplements, restricting their availability.

The oral medication ospemifene is intended only for the treatment of moderate-to-severe dyspareunia brought on by GSM. Ospemifene, an estrogen agonist that was approved in 2013, functions as a selective estrogen receptor modulator in the vagina but does not seem to activate breast and endometrial cells. Typically, women who prefer not to use vaginal products or who are unable to do so are given this daily oral option. Ospemifene and vaginal estrogen have not been compared in head-to-head studies, unlike prasterone.

Analysis of Key Players

The competitive landscape is a mix of specialized women’s health firms and global pharmaceutical giants focused on hormonal balance.

Leading companies operating in the global dyspareunia treatment market include:

• Duchesnay, Inc.
• AMAG Pharmaceuticals, Inc.
• Amneal Pharmaceuticals
• TherapeuticsMD, Inc.
• Myovant Sciences
• Novo Nordisk, Inc.
• Pfizer
• Viatris, Inc.

Strategic moves in 2026 highlight the “Generic Transition.” In December 2025, the FDA approved the first generic Estradiol Vaginal Insert, signaling a move toward more affordable, high-volume access for a broader patient demographic.

Recent Developments (2025–2026)

• On February 14, 2022, Duchesnay, Inc., a pharmaceutical company specializing in women’s health and part of the Duchesnay Pharmaceutical Group based in Blainville, Quebec, announced the first treatment launched to help postmenopausal women suffering from vaginal dryness and painful intercourse across Canada. Osphena (ospemifene tablets), a Selective Estrogen Receptor Modulator (SERM) now available across Canada, has been approved by Health Canada as a once-daily prescription treatment for this indication.
• On September 13, 2018, TherapeuticsMD, Inc., an innovative women’s healthcare company, announced the commercial availability of Imvexxy (estradiol vaginal inserts) 4 mcg dose in the U.S. Imvexxy 4 mcg is the lowest-dose vaginal estrogen product approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

Key Developments & Trends

• Telehealth-First Prescriptions: Direct-to-consumer (DTC) platforms offering virtual consults and discreet shipping for vaginal inserts and creams.
• Non-Hormonal SERMs: Rapid growth of Ospemifene as a safer alternative for patients with hormone-sensitive histories.
• Vaginal Laser & Energy-Based Therapies: Increasing use of fractional $CO_2$ lasers as a non-drug alternative for tissue rejuvenation.
• Dose-Sparing Innovations: Development of “soft-gel” and ultra-low-dose capsules to minimize systemic absorption.
• Focus on Cancer Survivors: Specialized clinics addressing dyspareunia in the 3.8 million breast cancer survivors in the US who cannot use traditional hormones.

Challenges

• Cultural Stigma: Despite progress, many women still consider painful intercourse a “normal” part of aging rather than a treatable medical condition.
• High Out-of-Pocket Costs: Specialized brands often face tier-3 or tier-4 insurance placement, leading to high co-pays.
• Side Effect Concerns: Persisting fears regarding the links between hormone replacement therapy (HRT) and cardiovascular or oncological risks.
• Under-Diagnosis: Lack of routine screening for sexual pain during standard annual gynecological exams.

Opportunities

• Personalized Compounding: Growing market for customized vaginal suppositories that combine lubricants with localized steroids.
• Over-the-Counter (OTC) Bridge: Developing high-end, medical-grade lubricants that serve as a gateway to prescription treatments.
• Menopause Management Apps: Integrating symptom tracking and treatment education into the booming “FemTech” app ecosystem.
• Unmet Need in Emerging Markets: Massive growth potential in Latin America and Southeast Asia as healthcare infrastructure modernizes.

Market Segmentation

➤ By Drug Type

• Estrogen Therapy (Market Leader ~59.4% share)
• Selective Estrogen Receptor Modulators (SERMs) (Fastest Growing)
• Prasterone (DHEA-based)
• Others (Cortical steroids, Antibiotics)

➤ By Route of Administration

• Topical/Vaginal (Dominant Segment – Creams, Inserts, Rings)
• Oral (High compliance for SERMs)
• Parenteral (Injectable therapies for complex cases)

➤ By Distribution Channel

• Retail Pharmacies (Market Leader ~39.4% share)
• Online/E-commerce Pharmacies (Fastest Growth)
• Hospital Pharmacies

Conclusion

The dyspareunia treatment market is moving from “Silence to Solutions.” Through 2035, the industry will be defined by accessibility and mechanism diversity. As non-hormonal options mature and telehealth removes barriers to care, the companies that provide discreet, affordable, and clinically safe interventions will successfully capture the growing demand for improved quality of life in postmenopausal health.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=85106&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com